Company Overview

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing a class of therapeutics known as bicyclic peptides, which the company refers to as “Bicycles.” The company operates primarily in the oncology and radiopharmaceutical sectors, with additional research activity in areas such as autoimmune and inflammatory diseases. Bicycle Therapeutics is publicly traded on Nasdaq under the ticker BCYC and is headquartered in Cambridge, United Kingdom, with significant operational presence in the United States.

The company’s core business centers on the discovery and development of targeted therapeutics designed to combine the pharmacological properties of biologics with the manufacturing and tissue penetration advantages of small molecules. Its primary revenue sources have historically included collaboration agreements, licensing arrangements, and milestone payments with pharmaceutical partners, while its long-term strategy is centered on commercialization of internally developed therapies. Bicycle Therapeutics was founded in 2009 as a spinout from the Medical Research Council Laboratory of Molecular Biology in Cambridge and evolved from platform discovery research into a clinical-stage oncology developer with multiple drug candidates in human trials.

Business Operations

Bicycle Therapeutics organizes its activities around discovery, clinical development, and strategic collaborations utilizing its proprietary Bicycle platform technology. The company’s lead therapeutic programs are focused on Bicycle Toxin Conjugates (BTCs), which are designed to deliver cytotoxic payloads directly to tumor cells while limiting systemic exposure. Key clinical assets have included zelenectide pevedotin (formerly BT8009), targeting Nectin-4, and other oncology candidates directed at EphA2 and MT1-MMP. The company is also advancing radiopharmaceutical programs through its Bicycle Radio Conjugates (BRCs) platform.

Operations span both the United Kingdom and United States, with research and development functions distributed across these regions. Bicycle Therapeutics maintains strategic partnerships with major pharmaceutical companies including Novartis, Genentech/Roche, and Ionis Pharmaceuticals. These collaborations have focused on oncology, radiopharmaceuticals, and oligonucleotide delivery technologies. The company’s proprietary peptide screening and conjugation technologies are considered core intellectual property assets supporting its therapeutic development pipeline.

Strategic Position & Investments

Bicycle Therapeutics’ strategic direction emphasizes advancing targeted oncology therapeutics with differentiated pharmacokinetic properties and improved tumor penetration compared with conventional antibody-drug conjugates. The company has prioritized expanding its clinical pipeline, particularly in solid tumors, while also investing in next-generation radiopharmaceutical applications. Management has consistently emphasized rapid systemic clearance and precision targeting as key differentiators of the Bicycle platform.

The company has entered multiple strategic collaborations and licensing agreements to broaden the application of its technology and diversify funding sources. Partnerships with Novartis and Genentech/Roche have supported external validation of the platform and provided non-dilutive capital through upfront payments and milestone structures. Bicycle Therapeutics has also increased investment in manufacturing capabilities, translational research, and clinical trial infrastructure as it advances later-stage development programs. Public disclosures indicate ongoing investment in radioconjugate development and tumor-targeted delivery technologies as emerging growth areas.

Geographic Footprint

Bicycle Therapeutics is headquartered in Cambridge, England, a major biotechnology hub, and maintains significant operations in Cambridge, Massachusetts. The company’s footprint reflects a transatlantic operating model intended to support both European scientific research and access to the U.S. biotechnology and capital markets ecosystem.

The company’s clinical and collaborative activities extend across North America, Europe, and selected international research networks. Its partnerships with multinational pharmaceutical companies provide broader international exposure and potential commercialization reach beyond its direct operating infrastructure. Bicycle Therapeutics’ investor base and regulatory activities are also strongly tied to the United States, where the company is listed on Nasdaq and conducts substantial clinical development operations.

Leadership & Governance

Bicycle Therapeutics was co-founded by Sir Gregory Winter, a Nobel Prize-winning scientist recognized for work in antibody engineering, alongside members of the Cambridge scientific community. The company’s leadership has emphasized innovation-driven oncology development, disciplined clinical execution, and strategic partnerships designed to maximize the utility of the Bicycle platform across multiple therapeutic modalities.

Key executives include:

• Kevin Lee – Chief Executive Officer
• Peter Krasniqi – Chief Financial Officer
• Christian Schade – Chief Business Officer
• Miriam Richman – Chief Medical Officer
• David Campbell – Chief Scientific Officer

The company operates under a governance structure typical of publicly listed biotechnology firms, with oversight provided by a board of directors and committees responsible for audit, compensation, and corporate governance matters. Leadership communications and public filings indicate a strategic focus on clinical data generation, capital discipline, and long-term platform expansion.